Adenocarcinoma  >>  Tecentriq (atezolizumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
NCT02543645: A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Checkmark Initiation of enrollment in P1/2 trial in combination with varlilumab in renal cell carcinoma
Dec 2015 - Dec 2015: Initiation of enrollment in P1/2 trial in combination with varlilumab in renal cell carcinoma
Checkmark MPDL3280A in combination with varlilumab for RCC
Aug 2015 - Aug 2015: MPDL3280A in combination with varlilumab for RCC
Terminated
1
18
US
Combination of Varlilumab and Atezolizumab
Celldex Therapeutics, Genentech, Inc.
Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer
04/17
05/17

Download Options